Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Hadeer M Abdelaziz, Ahmed O Elzoghby, Maged W Helmy, Magda W Samaha, Jia-You Fang & May S Freag. (2019) Liquid crystalline assembly for potential combinatorial chemo–herbal drug delivery to lung cancer cells. International Journal of Nanomedicine 14, pages 499-517.
Read now
Read now
Rudra Pangeni, Jeong Uk Choi, Vijay Kumar Panthi, Youngro Byun & Jin Woo Park. (2018) Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. International Journal of Nanomedicine 13, pages 3329-3351.
Read now
Read now
BaoHui Han, LuLu Yang, Xin Wang & LuanDi Yao. (2018) Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. OncoTargets and Therapy 11, pages 2121-2129.
Read now
Read now
Wei-Xiang Qi, Li-na Tang, Ai-na He, Zan Shen, Feng Lin & Yang Yao. (2012) Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Current Medical Research and Opinion 28:4, pages 643-650.
Read now
Read now
Jens Benn Sørensen. (2011) Pharmacokinetic evaluation of pemetrexed. Expert Opinion on Drug Metabolism & Toxicology 7:7, pages 919-928.
Read now
Read now
Articles from other publishers (29)
Huiyan Piao, Goeun Choi, N. Sanoj Rejinold, Jin Yu, Soo-Jin Choi & Jin-Ho Choy. (2023) Pemetrexed-layered double hydroxide with Eudragit® S100; 2D van der Waals nanohybrid with drug delivery function. Journal of Industrial and Engineering Chemistry.
Crossref
Crossref
Sharareh Seifi, Babak Salimi, Zahra Esfahani Monfared, Cyrus Sabahi, Hamidreza Kafi & Adnan Khosravi. (2023) Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance. Journal of Pharmaceutical Policy and Practice 16:1.
Crossref
Crossref
Przemysław Biegański, Martina Godel, Chiara Riganti, Daniel Fábio Kawano, Joanna Kopecka & Konrad Kowalski. (2022) Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Bioorganic Chemistry 119, pages 105514.
Crossref
Crossref
Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J. Peters & Elisa Giovannetti. (2021) Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. Critical Reviews in Oncology/Hematology 166, pages 103454.
Crossref
Crossref
James Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, Jianxing He, Kazuhiko Nakagawa, Jin Hyoung Kang, Joo-Hang Kim, Rebecca R. Hozak, Tuan Stevon Nguyen, Wan Li Zhang, Sotaro Enatsu, Tarun Puri & Mauro Orlando. (2020) A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. Journal of Thoracic Oncology 15:1, pages 91-100.
Crossref
Crossref
Nunes, Diniz, Moreira-Barbosa, Constâncio, Silva, Oliveira, Soares, Paulino, Cunha, Rodrigues, Antunes, Henrique & Jerónimo. (2019) Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies. Journal of Clinical Medicine 8:9, pages 1500.
Crossref
Crossref
Bo Li, Junkai Zhang, Ya Su, Yiling Hou, Zhenguo Wang, Lin Zhao, Shengkai Sun & Hao Fu. (2019) Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism. Molecular Medicine Reports.
Crossref
Crossref
Rosa Camerlingo, Roberta Miceli, Laura Marra, Giuseppina Rea, Igea D’Agnano, Marta Nardella, Roberta Montella, Alessandro Morabito, Nicola Normanno, Virginia Tirino & Gaetano Rocco. (2019) Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation. PLOS ONE 14:7, pages e0219597.
Crossref
Crossref
Camila Ribeiro de Arruda Monteiro, Jean Henri Maselli Schoueri, Debora Terra Cardial, Lívia de Castro Linhares, Karine Corcione Turke, Lia Vineyard Steuer, Levy Werneck de Almeida Menezes, Igor Luiz Argani, Claudia Sette, Daniel de Iracema Gomes Cubero & Auro del Giglio. (2019) Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients. Revista da Associação Médica Brasileira 65:5, pages 611-617.
Crossref
Crossref
Yong Song, Qing Zhou, Xin Zhang, Gong-Yan Chen, Dian-Sheng Zhong, Zhuang Yu, Ping Yu, Yi-Ping Zhang, Jian-Hua Chen, Yi Hu, Guo-Sheng Feng, Xia Song, Qiang Shi, Lu Lu Yang, Luan Di Yao, Lu Jing Zhan, Fan Yang & Yi-Long Wu. (2018) Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). Lung Cancer 123, pages 7-13.
Crossref
Crossref
Fahima Dilnawaz & Sanjeeb K Sahoo. (2018) Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy. ACS Applied Nano Materials 1:2, pages 730-740.
Crossref
Crossref
James Chih-Hsin Yang, Tony Mok, Baohui Han, Mauro Orlando, Tarun Puri & Keunchil Park. (2018) A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer 19:1, pages 27-34.
Crossref
Crossref
Hui Xia, Wen Zhang, Baoshi Zhang, Yingnan Zhao, Yunlong Zhao, Shaojun Li & Yang Liu. (2017)
miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cells
in vitro
. Oncotarget 8:49, pages 85442-85451.
Crossref
Crossref
Xiaoguang Huang, Shihong Yue, Chuanlei Wang & Huaxiang Wang. (2017) Optimal three-dimensional reconstruction for lung cancer tissues. Technology and Health Care 25, pages 423-434.
Crossref
Crossref
Yinliang Qi, Yuanchang Dai & Shuyu Gui. (2016) Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC. Clinical and Experimental Pharmacology and Physiology 43:10, pages 1004-1012.
Crossref
Crossref
Guangsheng Zhai, Gaozhong Li, Bo Xu, Tongfu Jia, Yinping Sun, Jianbo Zheng & Jianbin Li. (2016) miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1. Bioscience Reports 36:3.
Crossref
Crossref
W Ma, C-n Ma, X-d Li & Y-j Zhang. (2016) Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer. Cancer Gene Therapy 23:2-3, pages 66-71.
Crossref
Crossref
Tomohiro Tamura, Gen Ohara, Katsunori Kagohashi, Mio Kawaguchi, Koichi Kurishima & Hiroaki Satoh. (2016) Pemetrexed and bevacizumab‑containing chemotherapy for pleomorphic carcinoma of the lung. Molecular and Clinical Oncology.
Crossref
Crossref
Rongrong Zhu, Qingxiu Wang, Yanjing Zhu, Zhaoqi Wang, Haixia Zhang, Bin Wu, Xianzheng Wu & Shilong Wang. (2016) pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomaterialia 29, pages 320-332.
Crossref
Crossref
Yongfu Ma, Hui Xia, Yang Liu & Min Li. (2014) Silencing miR-21 Sensitizes Non-Small Cell Lung Cancer A549 Cells to Ionizing Radiation through Inhibition of PI3K/Akt. BioMed Research International 2014, pages 1-6.
Crossref
Crossref
Hui Xia, Wen Zhang, Yingjie Li, Nannan Guo & Changhai Yu. (2014)
EZH2 Silencing with RNA Interference Induces G
2
/M Arrest in Human Lung Cancer Cells
In Vitro
. BioMed Research International 2014, pages 1-8.
Crossref
Crossref
Christina M. Annunziata & Phillip A. Dennis. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
1
21
.
Emily Y. Chu & Heidi H. Kong. 2013. Dermatologic Principles and Practice in Oncology. Dermatologic Principles and Practice in Oncology
160
169
.
Jeffrey R. Infante, Silvia Novello, Wen Wee Ma, Grace K. Dy, Johanna C. Bendell, Anne Huff, Qiong Wang, A. Benjamin Suttle, Robert Allen, Chun-Fang Xu, Lone H. Ottesen, Howard A. BurrisIIIIII & Alex A. Adjei. (2012) Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Investigational New Drugs 31:4, pages 927-936.
Crossref
Crossref
Zhiwei Wang. (2013) CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells. International Journal of Oncology.
Crossref
Crossref
HUI XIA, CHANG-HAI YU, YIMING ZHANG, JIANQI YU, JIE LI, WEN ZHANG, BAOSHI ZHANG, YINGJIE LI & NANNAN GUO. (2012) EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo. Oncology Letters 4:1, pages 135-140.
Crossref
Crossref
Sumitra THONGPRASERT, Sirana TINMANEE & Unchalee PERMSUWAN. (2012) Cost‐utility and budget impact analyses of gefitinib in second‐line treatment for advanced non‐small cell lung cancer from Thai payer perspective. Asia-Pacific Journal of Clinical Oncology 8:1, pages 53-61.
Crossref
Crossref
Cornelia Then, Jobst C. von Einem, Daniel Müller, Michael J. Flaig, Rudolf M. Huber & Martin Reincke. (2012) Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome. Onkologie 35:12, pages 783-786.
Crossref
Crossref
Shinichiro Motohashi, Yoshitaka Okamoto, Ichiro Yoshino & Toshinori Nakayama. (2011) Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clinical Immunology 140:2, pages 167-176.
Crossref
Crossref